

HALOZYME THERAPEUTICS INC

Form 8-K

December 16, 2005

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
December 16, 2005
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)**

| | | |
|---|--|--------------------------------------|
| Nevada | 000-49616 | 88-0488686 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 11588 Sorrento Valley Road, Suite 17, San Diego, California | | 92121 |
| (Address of principal executive offices) | | (Zip Code) |
| | Registrant's telephone number, including area code: (858) 794-8889 | |
| | Not Applicable | |

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

Item 8.01 Other Events.
SIGNATURES

Table of Contents

Item 8.01 Other Events.

On December 16, 2005, Halozyme Therapeutics, Inc. (Halozyme) closed its previously reported registered direct offering of 10,000,000 shares of Halozyme s common stock to certain institutional investors at a price of \$1.75 per share. The aggregate gross proceeds from the direct offering were approximately \$17.5 million. The net proceeds, after deducting the placement agents fee and other estimated offering expenses, were approximately \$16.1 million.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Halozyme Therapeutics, Inc.

December 16, 2005

By: /s/ David A. Ramsay

David A. Ramsay

Secretary and Chief Financial Officer